Cytotoxic T lymphocyte (CTL) responses human cytomegalovirus pp65, IE1- Exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs

Journal of Infectious Diseases

Volumn 181, Issue 5, 2000, Pages 1537-1546

  Gyulai, Zsofia ^c   Endresz, Valeria ^c   Burian, Katalin ^c   Pincus, Steve ^b   Toldy, Joseph ^c   Cox, William I ^b   Meric, Claude ^d   Plotkin, Stanley ^a   Gönczöl, Eva ^c   Berencsi, Klara ^e  

^a Pasteur Merieux Connaught   (United States)

^b Virogenetics Corporation   (United States)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Pasteur Merieux Connaught   (France)

^e WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN IE1; PROTEIN P 150; PROTEIN P28; SYNAPTOTAGMIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; EXON; HELPER CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MEMORY CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CONTINENTAL POPULATION GROUPS; CYTOMEGALOVIRUS; EXONS; HUMANS; IMMEDIATE-EARLY PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; REFERENCE VALUES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 0008120151     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315445     Document Type: Article

References (40)

1. 1. Hillyer CD, Snydman DR, Berkman EM. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. Transfusion 1990;30:659-66.
2. 2. Zaia JA. Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 1990;27:5-10.
3. 3. Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, Alford CA. Congenital cytomegalovirus infection. N Engl J Med 1977;296:1254-8.
4. 4. Quinnan GV, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow transplant recipients. N Engl J Med 1982;307:7-13.
5. 5. Quinnan GV, Burns WH, Kirmani N, et al. HLA restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 1984;6:156-63.
6. 6. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-80.
7. 7. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999;180:247-53.
8. + cytotoxic T lymphocyte responses to human cytomegalovirus in immunodeficient humans by the adoptive transfer of T cell clones. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Elsevier Science Publishers, 1993: 155-64.
9. 9. Walter EA, Philip MD, Greenberg PD, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333: 1038-44.
10. 10. Gilbert MJ, Riddell SR, Li C-R, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993;67:3461-9.
11. + virus specific cytotoxic T lymphocytes. J Med Virol 1994;43: 103-10.
12. 12. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
13. 13. Boppana SB, Britt WJ. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 1996;222:293-6.
14. 14. Diamond DJ, York J, Sun J-Y, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997;90:1751-67.
15. 15. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T cells. J Exp Med 1988;168:919-31.
16. 16. Alp NJ, Allport TD, Van-Zanten J, Rodgers B, Sissons JGP, Borysiewicz LK. Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. J Virol 1991;65:4812-20.
17. 17. Utz U, Koenig S, Coligan JE, Biddison WE. Presentation of three different viral peptides, HTLV-1 tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J Immunol 1992;149:214-21.
18. 18. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-2.
19. 19. Hopkins JI, Fiander AN, Evans AS, Delchambre M, Gheysen D, Borysiewicz LK. Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. J Med Virol 1996;49:124-31.
20. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999;73:8179-84.
21. 21. Landini MP, Michelson S. Human cytomegalovirus proteins. Prog Med Virol 1988;35:152-85.
22. 22. Gönczöl E, Furlini G, Ianacone J, Plotkin SA. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986;14:37-41.
23. 23. Endresz V, Kari L, Berencsi K, et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 1999;17:50-8.
24. 24. Akrigg A, Wilkinson GWG, Oram JD. The structure of the major immediate early gene of human cytomegalovirus strain AD169. Virus Res 1985;2: 107-21.
25. 25. Gönczöl E, Berencsi K, Pincus S, et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13:1080-5.
26. 26. Panicali D, Davis SW, Mercer SR, Paoletti E. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol 1981;37:1000-10.
27. 27. Perkus ME, Goebel SJ, Davis SW, et al. Vaccinia virus host range genes. Virology 1990;179:276-86.
28. 28. Lefkovits I, Waldmann H. Limiting dilution analysis of cells of the immune system. Cambridge: Cambridge University Press, 1979:60-82.
29. 29. Rice GPA, Schrier RD, Oldstone MBA. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 1984;81:6134-8.
30. 30. Fish KN, Britt W, Nelson JA. A novel mechanism for persistence of human cytomegalovirus in macrophages. J Virol 1996;70:1855-62.
31. 31. Lathey JL, Spector SA. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol 1991;65:6371-5.
32. 32. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus docs not require endogenous viral gene expression. J Immunol 1991;146:2795-804.
33. 33. Reddehase MJ, Koszinowski UH. Significance of herpesvinis immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 1984;312:369-71.
34. + T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987;61:3102.
35. 35. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class-I restricted T lymphocytes. Nature 1989;337:651-3.
36. 36. Holtappels R, Podlech J, Geginat G, Steffens H-P, Thomas D, Reddehase MJ. Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol 1998;72:7201-12.
37. 37. Kim S, Yu SS, Lee IS, et al. Human cytomegalovirus IE1 protein activates AP-1 through a cellular protein kinase(s). J Gen Virol 1999;80:961-9.
38. 38. Johnson RA, Yurochko AD, Poma EE, Zhu L, Huang E-S. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. J Gen Virol 1999;80 :1293-1303.
39. 39. Pajovic S, Wong EL, Black AR, Azizkhan JC. Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins. Mol Cell Biol 1997;17:6459-64.
40. 40. Liu Y-NC, Klaus A, Kari B, Stinski MF, Eckhardt J, Gehrz RC. The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B-and T-cell immune responses in humans. J Virol 1991;65:1644-8.